An Overview of Sugammadex

Introduction Sugammadex is a unique reversal agent for aminosteroid-induced neuromuscular blockade. Year Milestone 2000s Recognition of the need for a more effective reversal agent for neuromuscular blockade. 2001 Initiation of clinical trials for sugammadex (then known as Org 25969). 2008 Approval for clinical use in Europe and Australia; marketed as Bridion by Merck & Co. … Read more